These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 36652346

  • 1. Role of neoadjuvant treatment in resectable pancreatic cancer according to vessel invasion and increase of CA19-9 levels.
    Kim HS, Lee M, Han Y, Kang JS, Kang YH, Sohn HJ, Kwon W, Lee DH, Jang JY.
    J Hepatobiliary Pancreat Sci; 2023 Jul; 30(7):924-934. PubMed ID: 36652346
    [Abstract] [Full Text] [Related]

  • 2. Examining neoadjuvant treatment candidates in resectable pancreatic cancer based on tumor-vessel interactions and CA 19-9 levels: a retrospective cohort study.
    Jung HS, Han Y, Yun WG, Cho YJ, Lee M, Lee DH, Kwon W, Jang JY.
    Int J Surg; 2024 May 01; 110(5):2883-2893. PubMed ID: 38376856
    [Abstract] [Full Text] [Related]

  • 3. Reconsideration of the clinical impact of neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: A dual-institution collaborative clinical study.
    Yamada S, Hashimoto D, Yamamoto T, Yamaki S, Oshima K, Murotani K, Sekimoto M, Nakao A, Satoi S.
    Pancreatology; 2024 Jun 01; 24(4):592-599. PubMed ID: 38548551
    [Abstract] [Full Text] [Related]

  • 4. Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer.
    Imamura T, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Ohgi K, Todaka A, Fukutomi A, Aramaki T, Uesaka K.
    Br J Surg; 2019 Nov 01; 106(12):1649-1656. PubMed ID: 31626342
    [Abstract] [Full Text] [Related]

  • 5. Predictive value of baseline serum carbohydrate antigen 19-9 level on treatment effect of neoadjuvant chemoradiotherapy in patients with resectable and borderline resectable pancreatic cancer in two randomized trials.
    Doppenberg D, van Dam JL, Han Y, Bonsing BA, Busch OR, Festen S, van der Harst E, de Hingh IH, Homs MYV, Kwon W, Lee M, Lips DJ, de Meijer VE, Molenaar IQ, Nuyttens JJ, Patijn GA, van Roessel S, van der Schelling GP, Suker M, Versteijne E, de Vos-Geelen J, Wilmink JW, van Eijck CHJ, van Tienhoven G, Jang JY, Besselink MG, Groot Koerkamp B, Dutch Pancreatic Cancer Group.
    Br J Surg; 2023 Sep 06; 110(10):1374-1380. PubMed ID: 37440421
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcomes of preservation versus resection of portal/superior mesenteric vein during pancreaticoduodenectomy in pancreatic cancer patients who respond to neoadjuvant treatment: A retrospective cohort study.
    Chae YS, Jung HS, Yun WG, Han Y, Cho YJ, Lee M, Kwon W, Park JS, Jang JY.
    Int J Surg; 2024 Sep 23. PubMed ID: 39311909
    [Abstract] [Full Text] [Related]

  • 7. Portal or superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head carcinoma.
    Murakami Y, Satoi S, Motoi F, Sho M, Kawai M, Matsumoto I, Honda G, Multicentre Study Group of Pancreatobiliary Surgery (MSG-PBS).
    Br J Surg; 2015 Jun 23; 102(7):837-46. PubMed ID: 25877050
    [Abstract] [Full Text] [Related]

  • 8. Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer.
    Okada K, Uemura K, Kondo N, Sumiyoshi T, Seo S, Otsuka H, Serikawa M, Ishii Y, Tsuboi T, Murakami Y, Takahashi S.
    Langenbecks Arch Surg; 2022 Mar 23; 407(2):623-632. PubMed ID: 34609618
    [Abstract] [Full Text] [Related]

  • 9. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study.
    Kurahara H, Shinchi H, Ohtsuka T, Miyasaka Y, Matsunaga T, Noshiro H, Adachi T, Eguchi S, Imamura N, Nanashima A, Sakamoto K, Nagano H, Ohta M, Inomata M, Chikamoto A, Baba H, Watanabe Y, Nishihara K, Yasunaga M, Okuda K, Natsugoe S, Nakamura M.
    Langenbecks Arch Surg; 2019 Mar 23; 404(2):167-174. PubMed ID: 30649607
    [Abstract] [Full Text] [Related]

  • 10. Neoadjuvant chemoradiation is associated with decreased lymph node ratio in borderline resectable pancreatic cancer: A propensity score matched analysis.
    Peng JS, Morris-Stiff G, Ali NS, Wey J, Chalikonda S, El-Hayek KM, Walsh RM.
    Hepatobiliary Pancreat Dis Int; 2021 Feb 23; 20(1):74-79. PubMed ID: 32861576
    [Abstract] [Full Text] [Related]

  • 11. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing block of clinical T staging?
    Kang H, Kim SS, Sung MJ, Jo JH, Lee HS, Chung MJ, Park JY, Park SW, Song SY, Park MS, Bang S.
    Pancreatology; 2020 Jul 23; 20(5):952-959. PubMed ID: 32561070
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant therapy for pancreatic cancer: an intention-to-treat analysis.
    Okada K, Murakami Y, Uemura K, Kondo N, Nakagawa N, Seo S, Otsuka H, Takahashi S.
    Langenbecks Arch Surg; 2020 Aug 23; 405(5):623-633. PubMed ID: 32592044
    [Abstract] [Full Text] [Related]

  • 13. Clinical impact of preoperative tumour contact with superior mesenteric-portal vein in patients with resectable pancreatic head cancer.
    Ausania F, Sanchez-Cabus S, Senra Del Rio P, Borin A, Ayuso JR, Bodenlle P, Espinoza S, Cuatrecasas M, Conill C, Saurí T, Ferrer J, Fuster J, García-Valdecasas JC, Melendez R, Fondevila C.
    Langenbecks Arch Surg; 2021 Aug 23; 406(5):1443-1452. PubMed ID: 33475833
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.
    Jeong J, Choi DW, Choi SH, Heo JS, Jang KT.
    ANZ J Surg; 2015 Apr 23; 85(4):264-9. PubMed ID: 24641800
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion.
    Han S, Choi DW, Choi SH, Heo JS, Han IW, You YH.
    Asian J Surg; 2021 Jan 23; 44(1):313-320. PubMed ID: 32972828
    [Abstract] [Full Text] [Related]

  • 16. Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma.
    Giovinazzo F, Turri G, Katz MH, Heaton N, Ahmed I.
    Br J Surg; 2016 Feb 23; 103(3):179-91. PubMed ID: 26663252
    [Abstract] [Full Text] [Related]

  • 17. Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series.
    Ohgi K, Yamamoto Y, Sugiura T, Okamura Y, Ito T, Ashida R, Aramaki T, Uesaka K.
    Ann Surg Oncol; 2017 Sep 23; 24(9):2752-2761. PubMed ID: 28685356
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancers: Impact of the Combination Index of Sialyl-Lewis Antigen-Related Tumor Markers.
    Miyahara S, Takahashi H, Akita H, Sasaki K, Mukai Y, Iwagami Y, Hasegawa S, Yamada D, Tomimaru Y, Noda T, Wada H, Kobayashi S, Doki Y, Eguchi H.
    Ann Surg Oncol; 2024 May 23; 31(5):2932-2942. PubMed ID: 38368291
    [Abstract] [Full Text] [Related]

  • 19. Should the portal vein be routinely resected during pancreaticoduodenectomy for adenocarcinoma?
    Turrini O, Ewald J, Barbier L, Mokart D, Blache JL, Delpero JR.
    Ann Surg; 2013 Apr 23; 257(4):726-30. PubMed ID: 22968078
    [Abstract] [Full Text] [Related]

  • 20. Clinical significance of portal-superior mesenteric vein resection in pancreatoduodenectomy for pancreatic head cancer.
    Han SS, Park SJ, Kim SH, Cho SY, Kim YK, Kim TH, Lee SA, Woo SM, Lee WJ, Hong EK.
    Pancreas; 2012 Jan 23; 41(1):102-6. PubMed ID: 21775914
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.